Rodrigo E. Mendes
About
Rodrigo E. Mendes is a scholar working on Molecular Medicine, Infectious Diseases and Clinical Biochemistry.
According to data from OpenAlex, Rodrigo E. Mendes has authored 331 papers receiving a total of 10.1k indexed citations (citations by other indexed papers that have themselves been cited), including 190 papers in Molecular Medicine, 168 papers in Infectious Diseases and 137 papers in Clinical Biochemistry. Recurrent topics in Rodrigo E. Mendes's work include Antibiotic Resistance in Bacteria (190 papers), Antimicrobial Resistance in Staphylococcus (163 papers) and Bacterial Identification and Susceptibility Testing (137 papers). Rodrigo E. Mendes is often cited by papers focused on Antibiotic Resistance in Bacteria (190 papers), Antimicrobial Resistance in Staphylococcus (163 papers) and Bacterial Identification and Susceptibility Testing (137 papers). Rodrigo E. Mendes collaborates with scholars based in United States, Brazil and United Kingdom. Rodrigo E. Mendes's co-authors include Ronald N. Jones, Mariana Castanheira, Hélio S. Sader, Robert K. Flamm, David J. Farrell, Lalitagauri M. Deshpande, Michael A. Pfaller, Jennifer M Streit, James E. Ross and Ana Cristina Gales and has published in prestigious journals such as PLoS ONE, Clinical Infectious Diseases and CHEST Journal.
In The Last Decade
Rodrigo E. Mendes
321 papers receiving 9.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Rodrigo E. Mendes United States | 55 | 5.6k | 4.1k | 3.0k | 2.7k | 2.5k | 331 | 10.1k | ||
| Robert K. Flamm United States | 61 | 6.1k 1.1× | 3.6k 0.9× | 4.2k 1.4× | 1.9k 0.7× | 3.7k 1.4× | 338 | 11.6k | ||
| Jean B. Patel United States | 46 | 5.6k 1.0× | 5.2k 1.3× | 1.9k 0.6× | 3.6k 1.3× | 3.5k 1.4× | 78 | 13.3k | ||
| Daniel F. Sahm United States | 66 | 7.7k 1.4× | 3.1k 0.7× | 4.6k 1.6× | 2.4k 0.9× | 4.4k 1.7× | 270 | 13.5k | ||
| Helen W. Boucher United States | 34 | 3.8k 0.7× | 3.3k 0.8× | 2.2k 0.7× | 1.7k 0.6× | 2.2k 0.9× | 89 | 10.4k | ||
| Brandi Limbago United States | 42 | 3.9k 0.7× | 5.3k 1.3× | 1.3k 0.4× | 2.3k 0.8× | 3.5k 1.4× | 85 | 10.3k | ||
| Daryl J. Hoban Canada | 55 | 5.5k 1.0× | 2.4k 0.6× | 3.8k 1.3× | 1.5k 0.6× | 4.4k 1.7× | 210 | 10.7k | ||
| James A. Karlowsky Canada | 66 | 8.3k 1.5× | 3.4k 0.8× | 5.5k 1.8× | 2.5k 0.9× | 6.2k 2.4× | 326 | 15.1k | ||
| César A. Arias United States | 52 | 3.8k 0.7× | 6.0k 1.5× | 1.5k 0.5× | 3.3k 1.2× | 2.2k 0.9× | 261 | 12.8k | ||
| Mitchell J. Schwaber Israel | 40 | 4.6k 0.8× | 2.4k 0.6× | 1.3k 0.4× | 2.2k 0.8× | 2.1k 0.8× | 108 | 7.4k | ||
| George H. Talbot United States | 44 | 3.6k 0.6× | 3.7k 0.9× | 2.4k 0.8× | 1.6k 0.6× | 2.5k 1.0× | 120 | 10.1k |
Countries citing papers authored by Rodrigo E. Mendes
Since
Specialization
Citations
This map shows the geographic impact of Rodrigo E. Mendes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rodrigo E. Mendes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rodrigo E. Mendes more than expected).
Fields of papers citing papers by Rodrigo E. Mendes
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Rodrigo E. Mendes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rodrigo E. Mendes. The network helps show where Rodrigo E. Mendes may publish in the future.
Co-authorship network of co-authors of Rodrigo E. Mendes
This figure shows the co-authorship network connecting the top 25 collaborators of Rodrigo E. Mendes. A scholar is included among the top collaborators of Rodrigo E. Mendes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rodrigo E. Mendes. Rodrigo E. Mendes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Sader, Hélio S., et al.. (2025). Ceftobiprole activity against multidrug-resistant Staphylococcus aureus clinical isolates collected in the United States from 2016 through 2022. Antimicrobial Agents and Chemotherapy. 69(2). e0140224–e0140224.
2.
Huband, Michael D., et al.. (2025). Surveillance of omadacycline against 35,000 bacterial clinical isolates from the United States (2019-2023). Diagnostic Microbiology and Infectious Disease. 111(3). 116711–116711.
3.
Sader, Hélio S., John H. Kimbrough, Rodrigo E. Mendes, & Mariana Castanheira. (2024). Antimicrobial susceptibility of enterobacterales causing bloodstream infection in United States medical centres: comparison of aztreonam-avibactam with beta-lactams active against carbapenem-resistant enterobacterales. BMC Infectious Diseases. 24(1). 1242–1242.
4.
Moeck, Greg, Leanne B. Gasink, Rodrigo E. Mendes, et al.. (2024). Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection. Antimicrobial Agents and Chemotherapy. 68(7). e0023624–e0023624.
5.
Paukner, Susanne, et al.. (2023). 7-Year (2015–21) longitudinal surveillance of lefamulin in vitro activity against bacterial pathogens collected worldwide from patients with respiratory tract infections including pneumonia and characterization of resistance mechanisms. Journal of Antimicrobial Chemotherapy. 79(2). 360–369.
6.
Moeck, Greg, Leanne B. Gasink, Marcus Dörr, et al.. (2023). 2523. Outcomes by Resistance Phenotype and Genotype among Baseline Pathogen in Patients with Complicated Urinary Tract Infection (cUTI) in the Phase 3 CERTAIN-1 Study. Open Forum Infectious Diseases. 10(Supplement_2).
7.
Huband, Michael D., Rodrigo E. Mendes, Gina Morgan, Holly K. Huynh, & Mariana Castanheira. (2023). 2517. Activity of Sulbactam-durlobactam, Antibacterial Combinations, and Comparators Against a Challenge Set of 66 Acinetobacter baumannii-calcoaceticus Species Complex Isolates. Open Forum Infectious Diseases. 10(Supplement_2).
8.
Biagi, Mark, et al.. (2022). Aztreonam in combination with imipenem-relebactam against clinical and isogenic strains of serine and metallo-β-lactamase-producing enterobacterales. Diagnostic Microbiology and Infectious Disease. 103(2). 115674–115674.
9.
Deshpande, Lalitagauri M., et al.. (2021). Characterization of a vga gene variant recovered from a Staphylococcus saprophyticus causing a community-acquired urinary tract infection: report from the SENTRY Antimicrobial Surveillance Program 2017. Diagnostic Microbiology and Infectious Disease. 100(4). 115398–115398.
10.
Biagi, Mark, et al.. (2020). Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia. Antimicrobial Agents and Chemotherapy. 64(12).
11.
Pfaller, Michael A., Rodrigo E. Mendes, Jennifer M Streit, Patricia A. Hogan, & Robert K. Flamm. (2017). Five-Year Summary of In Vitro Activity and Resistance Mechanisms of Linezolid against Clinically Important Gram-Positive Cocci in the United States from the LEADER Surveillance Program (2011 to 2015). Antimicrobial Agents and Chemotherapy. 61(7).
12.
Castanheira, Mariana, Rodrigo E. Mendes, & Hélio S. Sader. (2016). Low Frequency of Ceftazidime-Avibactam Resistance among Enterobacteriaceae Isolates Carrying bla KPC Collected in U.S. Hospitals from 2012 to 2015. Antimicrobial Agents and Chemotherapy. 61(3).
13.
Castanheira, Mariana, Rodrigo E. Mendes, Ronald N. Jones, & Hélio S. Sader. (2016). Changes in the Frequencies of β-Lactamase Genes among Enterobacteriaceae Isolates in U.S. Hospitals, 2012 to 2014: Activity of Ceftazidime-Avibactam Tested against β-Lactamase-Producing Isolates. Antimicrobial Agents and Chemotherapy. 60(8). 4770–4777.
14.
Duncan, Leonard R, Jennifer I. Smart, Robert K. Flamm, et al.. (2016). Telavancin activity tested against a collection of Staphylococcus aureus isolates causing pneumonia in hospitalized patients in the United States (2013–2014). Diagnostic Microbiology and Infectious Disease. 86(3). 300–302.
15.
Mendes, Rodrigo E., Lalitagauri M. Deshpande, Andrew J. Costello, et al.. (2015). Genotypic Characterization of Methicillin-Resistant Staphylococcus aureus Recovered at Baseline from Phase 3 Pneumonia Clinical Trials for Ceftobiprole. Microbial Drug Resistance. 22(1). 53–58.
16.
Mendes, Rodrigo E., Hélio S. Sader, Robert K. Flamm, & Ronald N. Jones. (2014). Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide. Journal of Antimicrobial Chemotherapy. 69(6). 1579–1581.
17.
Farrell, David J., Rodrigo E. Mendes, James E. Ross, Hélio S. Sader, & Ronald N. Jones. (2011). LEADER Program Results for 2009: an Activity and Spectrum Analysis of Linezolid Using 6,414 Clinical Isolates from 56 Medical Centers in the United States. Antimicrobial Agents and Chemotherapy. 55(8). 3684–3690.
18.
Jones, Ronald N., D. J. Farrell, Rodrigo E. Mendes, & Hélio S. Sader. (2011). Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study. Journal of Antimicrobial Chemotherapy. 66(Supplement 3). iii69–iii80.
19.
Castanheira, Mariana, Lalitagauri M. Deshpande, Dilip Mathai, et al.. (2010). Early Dissemination of NDM-1- and OXA-181-Producing Enterobacteriaceae in Indian Hospitals: Report from the SENTRY Antimicrobial Surveillance Program, 2006-2007. Antimicrobial Agents and Chemotherapy. 55(3). 1274–1278.
20.
Mendes, Rodrigo E., et al.. (2000). In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.. PubMed. 4(5). 226–35.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Robert K. Flamm Breakdown of academic impact, for papers by Jean B. Patel Breakdown of academic impact, for papers by Daniel F. Sahm Breakdown of academic impact, for papers by Helen W. Boucher Breakdown of academic impact, for papers by Brandi Limbago Breakdown of academic impact, for papers by Daryl J. Hoban Breakdown of academic impact, for papers by James A. Karlowsky Breakdown of academic impact, for papers by César A. Arias Breakdown of academic impact, for papers by Mitchell J. Schwaber Breakdown of academic impact, for papers by George H. Talbot